JP2016512202A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512202A5 JP2016512202A5 JP2015561849A JP2015561849A JP2016512202A5 JP 2016512202 A5 JP2016512202 A5 JP 2016512202A5 JP 2015561849 A JP2015561849 A JP 2015561849A JP 2015561849 A JP2015561849 A JP 2015561849A JP 2016512202 A5 JP2016512202 A5 JP 2016512202A5
- Authority
- JP
- Japan
- Prior art keywords
- fibrosis
- alkenyl
- alkyl
- composition
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 13
- 206010016654 Fibrosis Diseases 0.000 claims 9
- 230000004761 fibrosis Effects 0.000 claims 9
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 7
- 230000002500 effect on skin Effects 0.000 claims 5
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000003176 fibrotic effect Effects 0.000 claims 3
- 201000002793 renal fibrosis Diseases 0.000 claims 3
- 231100000241 scar Toxicity 0.000 claims 3
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000009787 cardiac fibrosis Effects 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000428 dust Substances 0.000 claims 2
- 208000028208 end stage renal disease Diseases 0.000 claims 2
- 201000000523 end stage renal failure Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 206010035653 pneumoconiosis Diseases 0.000 claims 2
- 231100000397 ulcer Toxicity 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 208000033116 Asbestos intoxication Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 206010011985 Decubitus ulcer Diseases 0.000 claims 1
- 208000008960 Diabetic foot Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 208000032984 Intraoperative Complications Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 208000005230 Leg Ulcer Diseases 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 208000004210 Pressure Ulcer Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 201000010001 Silicosis Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 208000010123 anthracosis Diseases 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 206010003441 asbestosis Diseases 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 150000001879 copper Chemical class 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 239000007789 gas Substances 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 208000029570 hepatitis D virus infection Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 239000012678 infectious agent Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 229940125798 integrin inhibitor Drugs 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 229940075993 receptor modulator Drugs 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000004409 schistosomiasis Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 239000000779 smoke Substances 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 0 *c1c(*)c(*)c(*)c(*)c1* Chemical compound *c1c(*)c(*)c(*)c(*)c1* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361798269P | 2013-03-15 | 2013-03-15 | |
| US61/798,269 | 2013-03-15 | ||
| PCT/CA2014/000236 WO2014138906A1 (en) | 2013-03-15 | 2014-03-14 | Substituted aromatic compounds and related method for the treatment of fibrosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512202A JP2016512202A (ja) | 2016-04-25 |
| JP2016512202A5 true JP2016512202A5 (enExample) | 2017-04-13 |
| JP6448562B2 JP6448562B2 (ja) | 2019-01-09 |
Family
ID=51535669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561849A Expired - Fee Related JP6448562B2 (ja) | 2013-03-15 | 2014-03-14 | 線維症を治療するための置換芳香族化合物及び関連方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10023518B2 (enExample) |
| EP (1) | EP2970089B1 (enExample) |
| JP (1) | JP6448562B2 (enExample) |
| KR (1) | KR102196721B1 (enExample) |
| CN (2) | CN110105200B (enExample) |
| AR (1) | AR095429A1 (enExample) |
| AU (1) | AU2014231648B2 (enExample) |
| BR (1) | BR112015022008A2 (enExample) |
| CA (1) | CA2905621C (enExample) |
| CL (1) | CL2015002535A1 (enExample) |
| DK (1) | DK2970089T3 (enExample) |
| EA (1) | EA030651B1 (enExample) |
| ES (1) | ES2741439T3 (enExample) |
| IL (1) | IL241178B (enExample) |
| MX (1) | MX379424B (enExample) |
| MY (1) | MY180305A (enExample) |
| NZ (1) | NZ712797A (enExample) |
| PH (1) | PH12015502011B1 (enExample) |
| PL (1) | PL2970089T3 (enExample) |
| PT (1) | PT2970089T (enExample) |
| SG (1) | SG11201507408XA (enExample) |
| TW (1) | TWI689490B (enExample) |
| UY (1) | UY35402A (enExample) |
| WO (1) | WO2014138906A1 (enExample) |
| ZA (1) | ZA201507061B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
| US9200004B2 (en) | 2013-01-15 | 2015-12-01 | Incyte Holdings Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors |
| TWI689489B (zh) * | 2013-03-15 | 2020-04-01 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
| PE20160532A1 (es) | 2013-08-23 | 2016-05-21 | Incyte Corp | Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| EP3203998B1 (en) * | 2014-10-10 | 2021-03-10 | Liminal Biosciences Limited | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes |
| MY194308A (en) | 2014-10-10 | 2022-11-27 | Prometic Pharma Smt Ltd | Substituted aromatic compounds and pharmaceutical compostions for the prevention and treatment of osteoporosis |
| JP6720169B2 (ja) * | 2014-11-12 | 2020-07-08 | リミナル・バイオサイエンシーズ・リミテッドＬｉｍｉｎａｌ ＢｉｏＳｃｉｅｎｃｅｓ Ｌｉｍｉｔｅｄ | 組織の自己修復及び再生のための置換芳香族化合物及び医薬組成物 |
| SG11201707555RA (en) * | 2015-03-18 | 2017-10-30 | Vectus Biosystems Ltd | Compositions for the treatment of kidney and/or liver disease |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| US20190144547A1 (en) * | 2015-11-23 | 2019-05-16 | Merck Patent Gmbh | Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders |
| US10463645B2 (en) * | 2016-05-19 | 2019-11-05 | Everfront Biotech Inc. | Method for delaying the onset of pulmonary fibrosis or treating pulmonary fibrosis |
| TWI684459B (zh) | 2016-12-15 | 2020-02-11 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種治療動脈粥樣硬化及其併發症的方法 |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| KR102126389B1 (ko) * | 2018-09-14 | 2020-06-25 | 셀라이온바이오메드 주식회사 | 벤즈히드릴티오 아세트아미드 화합물을 유효성분으로 포함하는 간 질환의 예방 또는 치료용 조성물 |
| AU2019358595B2 (en) | 2018-10-11 | 2025-04-17 | Basf As | Aromatic compounds and pharmaceutical uses thereof |
| IL302014A (en) * | 2020-10-06 | 2023-06-01 | Pharmaceutique Ingenew Inc | Substituted aromatic compounds and pharmaceutical compositions thereof |
| KR102543789B1 (ko) * | 2021-03-08 | 2023-06-20 | 주식회사 온코크로스 | 토르세미드 및 크로몰린을 포함하는 대사질환 예방 또는 치료용 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020183519A1 (en) * | 2001-03-13 | 2002-12-05 | Herbert Nar | Antithrombotic carboxylic acid amides |
| BRPI0711228A2 (pt) * | 2006-05-26 | 2012-06-19 | Auspex Pharmaceuticals Inc | "composto, método de tratar um mamìfero que sofre de um doença ou de uma condição envolvendo as enzimas ciclooxiganase, composição farmacêutica, processo para e deuteração de um composto pelatroca de pelomenos um átomo de hidrogênio do dito composto com um átomo do deutério e processo para preparar m composto" |
| CN101616583A (zh) * | 2007-02-08 | 2009-12-30 | 爱密斯菲尔科技公司 | 苯烷基羧酸输送剂 |
| JP2012526052A (ja) * | 2009-05-04 | 2012-10-25 | プロメティック・バイオサイエンシーズ・インコーポレイテッド | 置換芳香族化合物およびその薬学的使用 |
| DK2427417T3 (da) * | 2009-05-04 | 2014-01-20 | Prometic Biosciences Inc | Salte af 3-pentylphenyleddikesyre og farmaceutiske anvendelser deraf |
| AT509045B1 (de) * | 2010-01-29 | 2011-06-15 | Planta Naturstoffe Vertriebsges M B H | Verbindungen zur behandlung von asthma bronchiale |
-
2014
- 2014-03-12 TW TW103108723A patent/TWI689490B/zh not_active IP Right Cessation
- 2014-03-13 UY UY0001035402A patent/UY35402A/es not_active Application Discontinuation
- 2014-03-13 AR ARP140100973A patent/AR095429A1/es unknown
- 2014-03-14 CN CN201910355464.7A patent/CN110105200B/zh not_active Expired - Fee Related
- 2014-03-14 SG SG11201507408XA patent/SG11201507408XA/en unknown
- 2014-03-14 ES ES14764458T patent/ES2741439T3/es active Active
- 2014-03-14 PL PL14764458T patent/PL2970089T3/pl unknown
- 2014-03-14 CN CN201480013578.9A patent/CN105189438A/zh active Pending
- 2014-03-14 NZ NZ712797A patent/NZ712797A/en not_active IP Right Cessation
- 2014-03-14 CA CA2905621A patent/CA2905621C/en active Active
- 2014-03-14 MX MX2015011878A patent/MX379424B/es unknown
- 2014-03-14 EP EP14764458.7A patent/EP2970089B1/en active Active
- 2014-03-14 PT PT14764458T patent/PT2970089T/pt unknown
- 2014-03-14 MY MYPI2015002293A patent/MY180305A/en unknown
- 2014-03-14 EA EA201591775A patent/EA030651B1/ru not_active IP Right Cessation
- 2014-03-14 DK DK14764458.7T patent/DK2970089T3/da active
- 2014-03-14 AU AU2014231648A patent/AU2014231648B2/en not_active Ceased
- 2014-03-14 WO PCT/CA2014/000236 patent/WO2014138906A1/en not_active Ceased
- 2014-03-14 BR BR112015022008-8A patent/BR112015022008A2/pt active Search and Examination
- 2014-03-14 US US14/776,328 patent/US10023518B2/en active Active
- 2014-03-14 KR KR1020157029293A patent/KR102196721B1/ko not_active Expired - Fee Related
- 2014-03-14 JP JP2015561849A patent/JP6448562B2/ja not_active Expired - Fee Related
-
2015
- 2015-09-03 IL IL241178A patent/IL241178B/en active IP Right Grant
- 2015-09-09 PH PH12015502011A patent/PH12015502011B1/en unknown
- 2015-09-09 CL CL2015002535A patent/CL2015002535A1/es unknown
- 2015-09-22 ZA ZA2015/07061A patent/ZA201507061B/en unknown
-
2018
- 2018-04-04 US US15/945,408 patent/US10550066B2/en not_active Expired - Fee Related
-
2020
- 2020-02-03 US US16/780,316 patent/US11524930B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512202A5 (enExample) | ||
| JP2016510769A5 (enExample) | ||
| JP2021063088A5 (enExample) | ||
| CN110105200B (zh) | 用于治疗纤维化的经取代的芳族化合物及相关方法 | |
| JP2012525393A5 (enExample) | ||
| CR20220609A (es) | Antagonistas del receptor de lpa y usos de los mismos | |
| EA200971026A1 (ru) | Новые макроциклические ингибиторы репликации вируса гепатита с | |
| JP2017523219A5 (enExample) | ||
| EA200971041A1 (ru) | Новые пептидные ингибиторы репликации вируса гепатита с | |
| WO2019143902A3 (en) | Substituted heterocycles as antiviral agents | |
| NZ586751A (en) | Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function | |
| JP2018507914A5 (enExample) | ||
| JP2018518537A5 (enExample) | ||
| RU2010144637A (ru) | Замещенные гамма-лактамы в качестве терапевтических агентов | |
| JP2014530900A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| RU2012118974A (ru) | Комбинации ингибитора pi3k и ингибитора мек | |
| JP2017523225A5 (enExample) | ||
| JP2017529389A5 (enExample) | ||
| JP2010530376A5 (enExample) | ||
| RU2012134510A (ru) | Применение агента, обладающего модифицирующими свойствами в отношении гормонов надпочечников | |
| JP2010505865A5 (enExample) | ||
| RU2013155509A (ru) | Применение ингибирования катепсина к для лечения и/или профилактики легочной гипертензии и/или сердечной недостаточности | |
| RU2013147739A (ru) | Фармацевтическая композиция | |
| JP2015508068A5 (enExample) |